Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has...
-
Portland, OR, May 04, 2026 (GLOBE NEWSWIRE) -- Jama Software®, the leader in intelligent engineering management, announced today that Jama Connect® is the first engineering management software to...
-
Dublin, April 16, 2026 (GLOBE NEWSWIRE) -- The "Automotive Smart Key Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's...
-
Portland, OR, April 14, 2026 (GLOBE NEWSWIRE) -- Jama Connect, the leader in requirements management software, has been recognized once again as the Best Requirements Management Software in the G2...
-
Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global radiation dose management market was valued at 764.2 million in 2024 and is expected to reach US$ 2,301.3 million by 2033, growing at a CAGR of...
-
Portland, OR, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Jama Software®, the industry leading platform for requirements management to release, announced today that Jama Connect® 9.32 has set new scalability...
-
Chicago, Jan. 21, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global radiation dose management market was valued at US$ 764.2 million in 2024 and is projected to hit...
-
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Application Life-Cycle Management (ALM) Software - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global...
-
Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Japan Autonomous Vehicle Market, By Region, Competition, Opportunities & Forecast, 2021-2031F" has been added to ResearchAndMarkets.com's...
-
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial...